Jennifer L. Good Sells 5,263 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $1,403,599.54. This represents a 2.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Trevi Therapeutics Trading Down 2.1 %

Shares of TRVI stock opened at $6.47 on Thursday. The firm has a market capitalization of $625.53 million, a price-to-earnings ratio of -14.70 and a beta of 0.90. The business’s 50-day moving average price is $4.76 and its 200-day moving average price is $3.83. Trevi Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Institutional investors have recently modified their holdings of the business. Summit Investment Advisors Inc. raised its position in Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after purchasing an additional 2,894 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Trevi Therapeutics in the fourth quarter worth approximately $49,000. Squarepoint Ops LLC bought a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $58,000. Finally, Intech Investment Management LLC acquired a new stake in Trevi Therapeutics during the 3rd quarter valued at approximately $63,000. Institutional investors own 95.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Needham & Company LLC reduced their target price on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, March 19th. Oppenheimer boosted their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. B. Riley reaffirmed a “buy” rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Trevi Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $17.56.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.